These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 8100642)

  • 41. Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia: a 12-month, randomized, naturalistic trial.
    Cipriani A; Accordini S; Nosè M; Purgato M; Girlanda F; Tansella M; Barbui C
    J Clin Psychopharmacol; 2013 Aug; 33(4):533-7. PubMed ID: 23775051
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of treatment refractory schizophrenia.
    Morrison DP
    Br J Psychiatry Suppl; 1996 Dec; (31):15-20. PubMed ID: 8968651
    [No Abstract]   [Full Text] [Related]  

  • 43. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study.
    de Haan L; van Bruggen M; Lavalaye J; Booij J; Dingemans PM; Linszen D
    Am J Psychiatry; 2003 Feb; 160(2):303-9. PubMed ID: 12562577
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV; Brown WA; Laughren TP
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clozapine--the neglected potential].
    Munitz H
    Harefuah; 2012 May; 151(5):298-300, 318, 317. PubMed ID: 22844735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Schizophrenia, violence, clozapine and risperidone: a review. The Special Hospitals Treatment Resistant Schizophrenia Research Group.
    Br J Psychiatry Suppl; 1996 Dec; (31):21-30. PubMed ID: 8968652
    [No Abstract]   [Full Text] [Related]  

  • 47. Optimizing outcomes in schizophrenia: long-acting depots and long-term treatment.
    Morrissette DA; Stahl SM
    CNS Spectr; 2012 Nov; 17 Suppl 1():10-21. PubMed ID: 23462201
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review.
    Vothknecht S; Schoevers RA; de Haan L
    Aust N Z J Psychiatry; 2011 Mar; 45(3):182-92. PubMed ID: 21438745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Arguments for early treatment of refractory schizophrenia].
    Lombertie ER; Salome N; Villegier P; Laghrissi-Thode F; Nassif F
    Encephale; 1995 Jun; 21 Spec No 3():29-33. PubMed ID: 7628338
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
    Dieterle DM; Ackenheil M; Müller-Spahn F; Kapfhammer HP
    Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):52-7. PubMed ID: 2883683
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Weight gain and clozapine].
    Jalenques I; Tauveron I; Albuisson E; Audy V
    Encephale; 1996 Oct; 22 Spec No 3():77-9. PubMed ID: 8954282
    [No Abstract]   [Full Text] [Related]  

  • 52. Bromocriptine as adjunctive therapy to clozapine in treatment-resistant schizophrenia.
    al-Semaan Y
    Can J Psychiatry; 1996 Sep; 41(7):484-5. PubMed ID: 8884041
    [No Abstract]   [Full Text] [Related]  

  • 53. [Atypical neuroleptics--the future of schizophrenia treatment?].
    Ebert D
    Fortschr Med; 1998 Jan; 116(3):22-8. PubMed ID: 9522541
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continuous versus intermittent neuroleptic therapy in schizophrenia.
    Jolley AG; Hirsch SR
    Drug Saf; 1993 May; 8(5):331-9. PubMed ID: 8099290
    [No Abstract]   [Full Text] [Related]  

  • 55. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
    Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
    Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome.
    Buchanan RW; Breier A; Kirkpatrick B; Ball P; Carpenter WT
    Am J Psychiatry; 1998 Jun; 155(6):751-60. PubMed ID: 9619146
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W; Möller HJ; Buchkremer G; Ohmann C; Riesbeck M; Wölwer W; Von Wilmsdorff M; Bottlender R; Klingberg S
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low dose medication strategies in the maintenance treatment of schizophrenia.
    Kane JM
    Schizophr Bull; 1983; 9(4):528-32. PubMed ID: 6140751
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The predictive value of psychopathological subclassifications for the neuroleptic treatment outcome in schizophrenia.
    Jarema M; Kacperczyk J; Kruszynski S
    Psychopathology; 1991; 24(3):141-6. PubMed ID: 1684443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.